Table 3.

Changes in Ishak Fibrosis Scores over the course of the HALT-C Trial for the 535 patients used in the morphometric analyses. Three were missing biopsy 2 and two were missing biopsy 3. The score was considered improved if it decreased by one or more stage and worsened if it decreased by one or more stage.

	n	Improved	Same	Worsened
Baseline to Biopsy 2	532	30%	43%	27%
IFN treated	261	31%	40%	29%
Control	271	30%	44%	26%
Month 24 to Biopsy 3	531	26%	41%	33%
IFN treated	261	28%	40%	32%
Control	270	24%	42%	34%
Baseline to Biopsy 3	533	32%	34%	34%
IFN treated	262	33%	34%	33%
Control	271	31%	34%	35%